Placement of a newly designed partially covered T- or Y-configured self-expanding metallic stent for hilar biliary obstruction: technical note

Jiao, Dechao; Wang, Jing; Han, Bingxin; Li, Zong-Ming; Wang, Yanli; Han, Xinwei

doi:10.1007/s11547-020-01196-w

Cited by 2 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inclusion criteria were: 1) age ≥ 18 and ≤ 75 years; 2) unresectable ECC patients accompanied by MOJ; 3) pathologic histology confirms the diagnosis of ECC by biopsy; 4) symptoms such as jaundice relate to biliary obstruction; 5) Eastern Co-operative Oncology Group Performance Status (ECOG-PS) score ≤ 2; and 6) Child-Pugh class A or B. Unresectable ECC should meet the following criteria of unresectability ( 18 ), for hilar cholangiocarcinoma, including distant metastatic disease (nonsatellite hepatic metastsses, lymph node metastases and distant metastases in other organ/sites), extensive local involvement of portal, hepatic artery and second biliary radicals, and inadequate future liver remnant(< 30% future liver remnant in patients with normal hepatic parenchyma and < 2 contiguous segments with adequate portal venous and hepatic arterial inflow adequate hepatic venous drainage, and adequate biliary drainage); for distal cholangiocarcinoma, including distant metastatic disease (distant metastases liver or other organs and lymph node metastases) and major vascular involvement of significant portal vein, superior mesenteric artery, and common or proper hepatic artery. respectively, MOJ should meet the following criteria ( 19 ), including clinical symptoms consistent with a diagnosis of biliary obstruction with jaundice, computed tomography (CT) or magnetic resonance imaging (MRI) indicating obstructive jaundice and a diagnosis of malignant pathology.…”

Section: Methodsmentioning

confidence: 99%

Safety and efficacy of biliary stenting combined with iodine-125 seed strand followed by hepatic artery infusion chemotherapy plus lenvatinib with PD-1 inhibitor for the treatment of extrahepatic cholangiocarcinoma with malignant obstructive jaundice

Lin,

Ke,

Chen

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

ObjectivesTo evaluate the efficacy and safety of biliary stenting implantation with iodine-125 seed strand (SI) followed by hepatic artery infusion chemotherapy (HAIC) plus lenvatinib (Len) with programmed death-1 (PD-1) inhibitor for patients diagnosed with extrahepatic cholangiocarcinoma (ECC) and malignant obstructive jaundice (MOJ).MethodsIn this single-center retrospective study, the data of ECC patients with MOJ from March 2015 to January 2023 was assessed. Using probability score matching (PSM), the selection bias of patients was reduced. Primary study outcomes included overall survival (OS) and progression-free survival (PFS). The OS and PFS were performed using the Kaplan–Meier method and evaluated with the log-rank test.ResultsA total of 104 patients were enrolled finally, including 52 patients treated with interventional therapy (SI+HAIC) plus Len with PD-1 inhibitor (SI+HAIC+Len+P group) and 52 patients treated with interventional therapy (SI+HAIC) plus lenvatinib (SI+HAIC+Len group). 26 pairs of patients were matched after PSM analysis. After PSM analysis, the median OS and PFS in the SI+HAIC+Len+P group were significantly longer compared to those in the SI+HAIC+Len group (OS:16.6 vs. 12.3 months, P = 0.001; PFS:12.6 vs 8.5 months, P = 0.004). The DCR was significantly different between groups (P = 0.039), while ORR not (P = 0.548). The addition of PD-1 inhibitor was generally well tolerated without treatment-associated mortality.ConclusionInterventional therapy (SI+HAIC) plus Len with PD-1 inhibitor was effective for ECC patients accompanied by MOJ with a manageable safety profile.

show abstract

Section: Methodsmentioning

confidence: 99%

Safety and efficacy of biliary stenting combined with iodine-125 seed strand followed by hepatic artery infusion chemotherapy plus lenvatinib with PD-1 inhibitor for the treatment of extrahepatic cholangiocarcinoma with malignant obstructive jaundice

Lin,

Ke,

Chen

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…A recent study used Y/T‐shaped stents, based on Gwon study, in 10 patients with malignant biliary trifurcation obstruction 54 . They achieved an occlusion rate of 30% and 20% of patients experienced late complications.…”

Section: Clinical Trial Of Eptfe Medical Devicesmentioning

confidence: 99%

ePTFE‐based biomedical devices: An overview of surgical efficiency

et al. 2021

View full text Add to dashboard Cite

Polytetrafluoroethylene (PTFE) is a ubiquitous material used for implants and medical devices in general because of its high biocompatibility and inertness: blood vessel, heart, table jawbone, nose, eyes, or abdominal wall can benefit from its properties in case of disease or injury. Its expanded version, ePTFE is an improved version of PTFE with better mechanical properties, which extends its medical applications. A material as frequently used as ePTFE with these exceptional properties deserves a review of its main uses, developments, and possibility of improvements. In this systematic review, we examined clinical trials related to ePTFE‐based medical devices from the literature. Then, we excluded all trials using ePTFE as a control to test other devices. ePTFE‐coated stents, hemodialysis and bypass grafts, guided bone and tissue regeneration membranes, hernia and heart repair and other devices are reviewed. The rates of success using these devices and their efficiency compared to other materials used for the same purposes are reported. ePTFE appears to be more or just as efficient compared to them. Some success rates remain low, suggesting the need of improvement ePTFE for medical applications.

show abstract

Placement of a newly designed partially covered T- or Y-configured self-expanding metallic stent for hilar biliary obstruction: technical note

Cited by 2 publications

References 19 publications

Safety and efficacy of biliary stenting combined with iodine-125 seed strand followed by hepatic artery infusion chemotherapy plus lenvatinib with PD-1 inhibitor for the treatment of extrahepatic cholangiocarcinoma with malignant obstructive jaundice

Safety and efficacy of biliary stenting combined with iodine-125 seed strand followed by hepatic artery infusion chemotherapy plus lenvatinib with PD-1 inhibitor for the treatment of extrahepatic cholangiocarcinoma with malignant obstructive jaundice

ePTFE‐based biomedical devices: An overview of surgical efficiency

Contact Info

Product

Resources

About